GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Inventory Turnover

Heidelberg Pharma AG (XTER:HPHA) Inventory Turnover : 0.00 (As of Feb. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Heidelberg Pharma AG's Cost of Goods Sold for the three months ended in Feb. 2024 was €0.03 Mil. Heidelberg Pharma AG's Average Total Inventories for the quarter that ended in Feb. 2024 was €10.73 Mil. Heidelberg Pharma AG's Inventory Turnover for the quarter that ended in Feb. 2024 was 0.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Heidelberg Pharma AG's Days Inventory for the three months ended in Feb. 2024 was 32,627.96.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Heidelberg Pharma AG's Inventory-to-Revenue for the quarter that ended in Feb. 2024 was 8.47.


Heidelberg Pharma AG Inventory Turnover Historical Data

The historical data trend for Heidelberg Pharma AG's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Inventory Turnover Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.97 23.93 9.66 3.29 0.54

Heidelberg Pharma AG Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.29 0.02 0.02 -

Heidelberg Pharma AG Inventory Turnover Calculation

Heidelberg Pharma AG's Inventory Turnover for the fiscal year that ended in Nov. 2023 is calculated as

Inventory Turnover (A: Nov. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Nov. 2023 ) / ((Total Inventories (A: Nov. 2022 ) + Total Inventories (A: Nov. 2023 )) / count )
=3.253 / ((2.1 + 9.957) / 2 )
=3.253 / 6.0285
=0.54

Heidelberg Pharma AG's Inventory Turnover for the quarter that ended in Feb. 2024 is calculated as

Inventory Turnover (Q: Feb. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Feb. 2024 ) / ((Total Inventories (Q: Nov. 2023 ) + Total Inventories (Q: Feb. 2024 )) / count )
=0.03 / ((9.957 + 11.497) / 2 )
=0.03 / 10.727
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heidelberg Pharma AG  (XTER:HPHA) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Heidelberg Pharma AG's Days Inventory for the three months ended in Feb. 2024 is calculated as:

Days Inventory =Average Total Inventories (Q: Feb. 2024 )/Cost of Goods Sold (Q: Feb. 2024 )*Days in Period
=10.727/0.03*365 / 4
=32,627.96

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Heidelberg Pharma AG's Inventory to Revenue for the quarter that ended in Feb. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Feb. 2024 ) / Revenue (Q: Feb. 2024 )
=10.727 / 1.267
=8.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Heidelberg Pharma AG Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG (XTER:HPHA) Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines